Literature DB >> 21399888

A comprehensive review of spinocerebellar ataxia type 2 in Cuba.

Luis Velázquez-Pérez1, Roberto Rodríguez-Labrada, Julio Cesar García-Rodríguez, Luis Enrique Almaguer-Mederos, Tania Cruz-Mariño, José Miguel Laffita-Mesa.   

Abstract

Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant cerebellar ataxia characterized by a progressive cerebellar syndrome associated to saccadic slowing, peripheral neuropathy, cognitive disorders, and other multisystem features. SCA2 is caused by the abnormal expansion of cytosine-adenine-guanine triplet repeats in the encoding region of the ATXN2 gene and therefore the expression of toxic polyglutamine expansions in the ataxin 2 protein, which cause progressive neuronal death of Purkinje cells in the cerebellum and several pontine, mesencephalic, and thalamic neurons among other cells. Worldwide, SCA2 is the second most frequent type of spinocerebellar ataxia, only surpassed by SCA3. Nevertheless, in Holguin, Cuba, the disease reaches the highest prevalence, resulting from a putative foundational effect. This review discusses the most important advances in the genotypical and phenotypical studies of SCA2, highlighting the comprehensive characterization reached in Cuba through clinical, neuroepidemiological, neurochemical, and neurophysiological evaluation of SCA2 patients and pre-symptomatic subjects, which has allowed the identification of new disease biomarkers and therapeutical opportunities. These findings provide guidelines, from a Cuban viewpoint, for the clinical management of the disease, its diagnosis, genetic counseling, and therapeutical options through rehabilitative therapy and/or pharmacological options.

Entities:  

Mesh:

Year:  2011        PMID: 21399888     DOI: 10.1007/s12311-011-0265-2

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  100 in total

1.  [Electromyographic pattern in patients and asymptomatic carriers of the SCA2 mutation].

Authors:  L Velázquez-Pérez; R Rodríguez-Labrada; J Medrano-Montero; G Sánchez-Cruz; N Canales-Ochoa; C Torres-Parra; Y González-Zaldívar
Journal:  Rev Neurol       Date:  2009 Jul 1-15       Impact factor: 0.870

2.  Involvement of the cranial nerves and their nuclei in spinocerebellar ataxia type 2 (SCA2).

Authors:  K Gierga; K Bürk; M Bauer; G Orozco Diaz; G Auburger; C Schultz; M Vuksic; L Schöls; R A I de Vos; H Braak; T Deller; U Rüb
Journal:  Acta Neuropathol       Date:  2005-05-19       Impact factor: 17.088

3.  CAG repeat length in RAI1 is associated with age at onset variability in spinocerebellar ataxia type 2 (SCA2).

Authors:  S Hayes; G Turecki; K Brisebois; I Lopes-Cendes; C Gaspar; O Riess; L P Ranum; S M Pulst; G A Rouleau
Journal:  Hum Mol Genet       Date:  2000-07-22       Impact factor: 6.150

4.  [Effects of a physical training program on quantitative neurological indices in mild stage type 2 spinocerebelar ataxia patients].

Authors:  I Pérez-Avila; J A Fernández-Vieitez; E Martínez-Góngora; R Ochoa-Mastrapa; M G Velázquez-Manresa
Journal:  Rev Neurol       Date:  2004 Nov 16-30       Impact factor: 0.870

5.  Saccade velocity is reduced in presymptomatic spinocerebellar ataxia type 2.

Authors:  L Velázquez-Pérez; C Seifried; M Abele; F Wirjatijasa; R Rodríguez-Labrada; N Santos-Falcón; G Sánchez-Cruz; L Almaguer-Mederos; R Tejeda; N Canales-Ochoa; M Fetter; U Ziemann; T Klockgether; J Medrano-Montero; J Rodríguez-Díaz; J M Laffita-Mesa; G Auburger
Journal:  Clin Neurophysiol       Date:  2009-02-07       Impact factor: 3.708

6.  Defining the boundaries of the response of sleep leg movements to a single dose of dopamine agonist.

Authors:  Mauro Manconi; Raffaele Ferri; Thom R Feroah; Marco Zucconi; Luigi Ferini-Strambi
Journal:  Sleep       Date:  2008-09       Impact factor: 5.849

7.  The parkinsonian phenotype of spinocerebellar ataxia type 2.

Authors:  Chin-Song Lu; Yah-Huei Wu Chou; Pei-Chi Kuo; Hsiu-Chen Chang; Yi-Hsin Weng
Journal:  Arch Neurol       Date:  2004-01

8.  Five year study of prenatal testing for Huntington's disease: demand, attitudes, and psychological assessment.

Authors:  S Adam; S Wiggins; P Whyte; M Bloch; M H Shokeir; H Soltan; W Meschino; A Summers; O Suchowersky; J P Welch
Journal:  J Med Genet       Date:  1993-07       Impact factor: 6.318

9.  Spinocerebellar ataxia type 2: clinical features of a pedigree displaying prominent frontal-executive dysfunction.

Authors:  E Storey; S M Forrest; J H Shaw; P Mitchell; R J Gardner
Journal:  Arch Neurol       Date:  1999-01

10.  Ethical and social issues in presymptomatic testing for Huntington's disease: a European Community collaborative study. European Community Huntington's Disease Collaborative Study Group.

Authors: 
Journal:  J Med Genet       Date:  1993-12       Impact factor: 6.318

View more
  28 in total

1.  Spinocerebellar ataxia type 2 neurodegeneration differentially affects error-based and strategic-based visuomotor learning.

Authors:  Israel Vaca-Palomares; Rosalinda Díaz; Roberto Rodríguez-Labrada; Jacqeline Medrano-Montero; Yaimé Vázquez-Mojena; Luis Velázquez-Pérez; Juan Fernandez-Ruiz
Journal:  Cerebellum       Date:  2013-12       Impact factor: 3.847

2.  Neurogenetics in Peru: clinical, scientific and ethical perspectives.

Authors:  Mario Cornejo-Olivas; Keren Espinoza-Huertas; Mario R Velit-Salazar; Diego Veliz-Otani; Indira Tirado-Hurtado; Miguel Inca-Martinez; Gustavo Silva-Paredes; Karina Milla-Neyra; Victoria Marca; Olimpio Ortega; Pilar Mazzetti
Journal:  J Community Genet       Date:  2015-05-27

3.  Lisuride reduces involuntary periodic leg movements in spinocerebellar ataxia type 2 patients.

Authors:  Luis Velázquez-Pérez; Roberto Rodríguez-Labrada; Lázaro Álvarez-González; Raúl Aguilera-Rodríguez; Mario Álvarez Sánchez; Nalia Canales-Ochoa; Lourdes Galicia Polo; Reyes Haro-Valencia; Jacqueline Medrano-Montero; Yaimeé Vázquez-Mojena; Arnoy Peña-Acosta; Annelié Estupiñán-Rodríguez; Noemí Rodríguez Pupo
Journal:  Cerebellum       Date:  2012-12       Impact factor: 3.847

4.  Oral zinc sulphate supplementation for six months in SCA2 patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Luis Velázquez-Pérez; Jorge Rodríguez-Chanfrau; Julio Cesar García-Rodríguez; Gilberto Sánchez-Cruz; Raúl Aguilera-Rodríguez; Roberto Rodríguez-Labrada; Julio Cesar Rodríguez-Díaz; Nalia Canales-Ochoa; Dennis Almaguer Gotay; Luis E Almaguer Mederos; José M Laffita Mesa; Marlene Porto-Verdecia; Consuelo González Triana; Noemí Rodríguez Pupo; Idania Hidalgo Batista; Orestes D López-Hernandez; Iverlis Díaz Polanco; Arelis Jayme Novas
Journal:  Neurochem Res       Date:  2011-05-12       Impact factor: 3.996

5.  A comprehensive clinical and genetic study of a large Mexican population with spinocerebellar ataxia type 7.

Authors:  L Velázquez-Pérez; C M Cerecedo-Zapata; O Hernández-Hernández; E Martínez-Cruz; Y S Tapia-Guerrero; R González-Piña; J Salas-Vargas; R Rodríguez-Labrada; R Gurrola-Betancourth; N Leyva-García; B Cisneros; J J Magaña
Journal:  Neurogenetics       Date:  2014-10-16       Impact factor: 2.660

6.  Comprehensive study of early features in spinocerebellar ataxia 2: delineating the prodromal stage of the disease.

Authors:  Luis Velázquez-Pérez; Roberto Rodríguez-Labrada; Edilia M Cruz-Rivas; Juan Fernández-Ruiz; Israel Vaca-Palomares; Jandy Lilia-Campins; Bulmaro Cisneros; Arnoy Peña-Acosta; Yaimeé Vázquez-Mojena; Rosalinda Diaz; Jonathan J Magaña-Aguirre; Tania Cruz-Mariño; Annelié Estupiñán-Rodríguez; José M Laffita-Mesa; Rigoberto González-Piña; Nalia Canales-Ochoa; Yanetza González-Zaldivar
Journal:  Cerebellum       Date:  2014-10       Impact factor: 3.847

Review 7.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

8.  Recessive spinocerebellar ataxia with paroxysmal cough attacks: a report of five cases.

Authors:  Luis Velázquez-Pérez; Rigoberto González-Piña; Roberto Rodríguez-Labrada; Raul Aguilera-Rodríguez; Lourdes Galicia-Polo; Yaimeé Vázquez-Mojena; Ana M Cortés-Rubio; Marla R Trujillo-Bracamontes; Cesar M Cerecedo-Zapata; Oscar Hernández-Hernández; Bulmaro Cisneros; Jonathan J Magaña
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

9.  Couples at risk for spinocerebellar ataxia type 2: the Cuban prenatal diagnosis experience.

Authors:  Tania Cruz-Mariño; Luis Velázquez-Pérez; Yanetza González-Zaldivar; Raúl Aguilera-Rodríguez; Miguel Velázquez-Santos; Yaimé Vázquez-Mojena; Annelié Estupiñán-Rodríguez; Rubén Reynaldo-Armiñán; Luis Enrique Almaguer-Mederos; José Miguel Laffita-Mesa; Victor Tamayo-Chiang; Milena Paneque
Journal:  J Community Genet       Date:  2013-05-15

10.  Large normal and intermediate alleles in the context of SCA2 prenatal diagnosis.

Authors:  Tania Cruz-Mariño; Jose Miguel Laffita-Mesa; Yanetza Gonzalez-Zaldivar; Miguel Velazquez-Santos; Raul Aguilera-Rodriguez; Annelie Estupinan-Rodriguez; Yaime Vazquez-Mojena; Patrick Macleod; Milena Paneque; Luis Velazquez-Perez
Journal:  J Genet Couns       Date:  2013-06-28       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.